ClinicalTrials.gg
TerminatedNCT05642468Updated May 4, 2026Results posted

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

A Phase 2 interventional study of Ritivixibat in Primary Sclerosing Cholangitis, sponsored by Albireo, an Ipsen Company. Terminated at 8 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Due to Sponsor decision, not due to any safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Cholangitis, Sclerosing with a site in Italy — 5 open to participants now, 8 under way, 2 of them phase 3. Cholangitis, Sclerosing · Italy.

Enrollment
10th of 10
18 · median 87
Started
2023
with 1 other
Phase 2
6 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
1 of 14
Albireo, an Ipsen Company

Among the 14 studies in Cholangitis, Sclerosing with a site in Italy, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 2, and was the 8th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

5 of the 14 studies in Cholangitis, Sclerosing with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Cholangitis, Sclerosing with a site in Italy, or all of them as a file.
02

Study summary

This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC).

Read the detailed description

This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC). Detailed Description: The primary goal of this study in participants with PSC with and without a Clinically Relevant Stricture (CRS) who are treated with A3907 is to assess the safety and tolerability of A3907 following repeat doses. Secondary goals include evaluation of the pharmacokinetic properties of A3907 (the study of how the body interacts with A3907 for the entire duration of exposure) and changes in safety parameters via laboratory testing such as liver enzymes, bile acid levels and markers of bile acid synthesis

03

Conditions studied

  • Primary Sclerosing Cholangitis

Keywords

  • PSC
  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Adults between 18 and 75 years of age (inclusive)
  2. Clinical diagnosis of large-duct PSC as evidenced by chronic cholestasis with evidence of more than 6 months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis. and historical evidence of elevated alkaline phosphatase (ALP).
  3. Willing to sign .
  4. Women of (WOCBP) and males with female partners of childbearing potential must agree to use . Women of nonchildbearing potential (WONCBP) have a confirmatory follicle-stimulating hormone [FSH] level ≥ 40 mIU/mL
  5. Alkaline phosphatase Phosphatase (ALP) value > 1.5 × (ULN) but ≤ 10 × ULNULN at Visit 1 (Screening Period). Before starting 12 weeks treatment variability of \< 30% between ALP values at Visit 1 and Visit 2 must be confirmed. If variability is > 30 % a third ALP value may be obtained. If the third ALP value meets >1.5 × ULN but ≤ 10 × ULN the patient can start the 12-week treatment period.
  6. Arms 1-3 Only: Total \< 1.5 × ULN (unless due to Gilberts Syndrome or hemolysis) and normal direct bilirubin.
  7. (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN
  8. Serum bile acid level > ULN
  9. Arms 1 - 3 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening Period that is consistent with PSC without a stricture.
  10. Arm 4 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening. Period that is consistent with PSC with a clinically relevant stricture, or clinically relevant bile duct obstruction (see Inclusion # 12 for additional information).
  11. Use of ursodeoxycholic acid (UDCA) with a total daily dose ≤ 23 mg/kg/day, or bile acid-binding resins are permitted, with a minimum of 3 months of stable treatment prior to the Screening Period, and expected to remain on a stable dose through the 12-week treatment period; or a minimum of 3 months off UDCA prior to the Screening Period if UDCA was recently discontinued.
  12. If a patient has inflammatory bowel disease (IBD) with a minimum disease duration of 4 weeks, this diagnosis should be documented. Inflammatory bowel disease should be in clinical remission or mildly active according to Crohn's Disease Activity Index (CDAI), partial Mayo score for Crohn's Disease (CD) and ulcerative colitis (UC), respectively (i.e. patients with CDAI score \< 220 and Mayo score \< 5, respectively). Patients with IBD should have had a colonoscopy performed within one year prior to the Screening Period with results showing no evidence of dysplasia or cancer
  13. Clinically stable for at least 3 months prior to the Screening Period.
  14. Arm 4 Only: One stable clinically relevant biliary stricture of at least 4 weeks duration on contrast-enhanced MRI/MRCP with > 75% reduction of duct diameter in the common bile duct or hepatic duct without suspicion of cholangiocarcinoma (further established by imaging and stable CA 19-9 below ULN repeated twice over 1 month), or cholelithiasis. Subjects may have signs or symptoms of worsening obstructive cholestasis (increasing jaundice, nausea, anorexia, steatorrhea and worsening or new onset pruritus), deterioration of liver function (i.e. decreasing count, increasing [INR]) and/could be listed for liver transplantation due to their clinically relevant biliary stricture.
  15. Arm 4 Only: MELD Score \< 35

Key exclusion criteria:

  1. Presence of documented secondary sclerosing cholangitis, small duct PSC, known or suspected overlapping clinical and histologic diagnosis of hepatitis or other causes of chronic liver disease
  2. Arm 1-3 Only: Biliary intervention within 3 months prior to study enrollment or planned.
  3. Arm 4 Only: Planned Biliary intervention between the Screening Period and baseline.
  4. Presence of alternative causes of chronic liver disease, including alcohol-associated liver disease, nonalcoholic steatohepatitis, primary biliary cholangitis, autoimmune hepatitis, or active or C.
  5. IBD with uncontrolled moderate to severe activity and/or on treatment with any , immunomodulator, or biologic agent for treatment of IBD (i.e. azathioprine, 6 mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with (including budesonide, budesonide MMX and beclomethasone) in the previous 4 weeks.
  6. History of infection or any other known relevant infection (e.g. tuberculosis).
  7. History of ileectomy, colostomy or colectomy.
  8. History of , including hepatocellular carcinoma and cholangiocarcinoma within the past 10 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
  9. Alpha-fetoprotein (AFP) > 20 ng/mL (at the Screening Visit) with 4-phase liver CT or MRI suggesting presence of liver cancer.
  10. History of transplants, including liver transplantation, or currently on active transplantation list (Arms 1 3). Arm 4 may be on an active liver transplantation list.
  11. Current or a history of hepatic decompensation events including, but not limited to ascites, encephalopathy, or history of esophageal variceal bleeding.
  12. Known or suspected overlapping clinical and histologic diagnosis of autoimmune hepatitis.
  13. Small duct PSC (evidence of PSC on historical liver histology, with normal bile ducts on cholangiography) without large duct PSC.
  14. Liver cirrhosis as assessed by any of the following:

    1. historical liver histology.
    2. liver stiffness measurement, assessed by FibroScan (FibroScan value > 14.4 kPa), in addition to clinical assessment and biochemical markers at the discretion of the investigator.
    3. signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal haemorrhage, and/or hepatic encephalopathy).
  15. History of bacterial cholangitis within 60 days prior to the Screening Period, or if the patient is on antibiotics for prophylaxis of recurrent cholangitis.
  16. Females who are pregnant, lactating, or breast feeding.
  17. History of alcohol or substance abuse in the previous 2 years. Patients must agree to refrain from illicit drug (including marijuana) and alcohol use during the study.
  18. to medicinal product (A3907) and its .
  19. Presence of any for undergoing MRCP (e.g. pacemaker).
  20. Any other condition or abnormality which, in the opinion of the investigator (or designee), may compromise the safety of the patient or interfere with the patient participating in, or completing the study.
  21. Administration of medications that slow gastrointestinal motility.
  22. Treatment with rifampicin.
  23. Exposure to oral drugs that are strong inhibitors or inducers of enzymes (e.g. grapefruit juice, ritonavir, itraconazole, ketoconazole, troleandomycin, rifampin, St John's wort, etc.) within 14 days prior to the Screening Period, or 5 half-lives of the drug, whichever is longer.
  24. Exposure to oral drugs that are substrates of CYP3A4 enzymes (e.g. codeine, ciclosporin [cyclosporin], diazepam, etc.) during the study.
  25. Treatment with vitamin D or fibrates, unless patient is on a stable dose ≥ 6 months prior to baseline.
  26. Exposure to an investigational drug, biologic agent, or medical device within 30 days prior to the Screening Period, or 5 half-lives of the study agent, whichever is longer.
  27. Platelet count \< 150 000/mm3
  28. Albumin level \< 3.0 g/dL
  29. INR > 1.3 (the patient may be treated with vitamin K intravenously, and if INR is ≤ 1.3 at resampling, the patient may be enrolled).
  30. Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease). A GGT or ALP isoenzymes should be obtained for confirmation of biliary origin;
  31. [GFR] \< 60 mL/min/1.73 m2
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    10 mg (Arm 1)

    10mg tablet A3907 administered orally once daily for 12 weeks.

    Drug: Ritivixibat

  • Experimental
    30 mg (Arm 2)

    30mg (3x10 mg tablets) A3907 administered orally once daily for 12 weeks.

    Drug: Ritivixibat

  • Experimental
    30 mg BID (Arm 3)

    30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.

    Drug: Ritivixibat

  • Experimental
    30 mg BID for CRS (Arm 4)

    30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.

    Drug: Ritivixibat

Interventions

  • DrugRitivixibat

    10mg tablet A3907 administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in an enrolled participant regardless of causal relationship with study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or an important medical event. A TEAE was any AE or worsening of an existing disease that occurred after the first dose of study drug and within the 14-day follow-up.

    Time frame: From first dose of study drug (Day 1) up to 14 days post last dose, approximately 112 days

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of A3907

    Blood samples were collected at specified timepoints to assess Cmax of A3907. The pharmacokinetic (PK) analysis was conducted after single dose (Day 0) and repeated dose administration (Day 98).

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Time t (Time of Last Quantifiable Plasma Concentration) (AUC0-t) of A3907

    Blood samples were collected at specified timepoints to assess AUC0-t of A3907.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98

  3. Change From Baseline to Week 12 in Serum and Urine Individual and Total Bile Acid Levels

    Blood and urine samples were collected at specified timepoints to assess serum and urine individual and total bile acid levels. Baseline=average of all screening results and results on day of planned single dose if both results were available. Otherwise, baseline=last non-missing assessment prior to study drug administration of planned single dose. CA=Cholic Acid; LCA=lithocholic acid; DCA=deoxycholic acid; CDCA=chenodeoxycholic acid; UDCA= ursodeoxycholic acid; GCA=glycocholic acid; GLCA=glycolithocholic acid; GDCA=glycodeoxycholic acid; GCDCA=glycochenodeoxycholic acid; GUDCA= glycoursodeoxycholic acid; TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid; TDCA=taurodeoxycholic acid; TLCA=taurolithocholic acid; TUDCA=tauroursodeoxycholic acid; S=sulfate. Calculated total bile acids without all UDCA bile acids is the sum of all individual bile acids excluding all UDCAs (UDCA, GUDCA, TUDCA). Conjugated bile acids include GCA, GLCA, GDCA, GCDCA, GUDCA, TCA, TCDCA, TDCA, TLCA, TUDCA.

    Time frame: Baseline (Day 1) and Week 12

  4. Change From Baseline to Week 12 in Liver Biochemical Tests (LBTs): Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Alkaline Phosphatase (ALP)

    Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.

    Time frame: Baseline (Day 1) and Week 12

  5. Change From Baseline to Week 12 in Liver Biochemical Tests: Total and Direct Bilirubin Levels

    Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.

    Time frame: Baseline (Day 1) and Week 12

  6. Change From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)

    Blood samples were collected at specified timepoints to assess C4. Baseline was defined as the assessment performed on the day of the planned single dose.

    Time frame: Baseline (Day 1) and Week 12

  7. Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19)

    Blood samples were collected at specified timepoints to assess FGF-19. Baseline was defined as the assessment performed on the day of the planned single dose.

    Time frame: Baseline (Day 1) and Week 12

07

Results

Posted May 4, 2026
Limitations and caveats
The study was terminated early due to Sponsor decision, not due to any safety concerns. No participant was enrolled in A3907 30 mg BID without CRS arm as the study was terminated prior to enrollment in that arm.

Participant flow

This Phase II, open-label study was conducted at 8 investigational sites in 4 countries in adults with primary sclerosing cholangitis (PSC). A total of 18 participants were enrolled in the study.

Participant flow — Overall Study
MilestoneA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Started864
Completed631
Not completed233
Withdrew: Adverse event001
Withdrew: Withdrawal by subject020
Withdrew: Exposure level exceeded safety margins200
Withdrew: Study terminated by sponsor012

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in an enrolled participant regardless of causal relationship with study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or an important medical event. A TEAE was any AE or worsening of an existing disease that occurred after the first dose of study drug and within the 14-day follow-up.

Time frame:
From first dose of study drug (Day 1) up to 14 days post last dose, approximately 112 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
TEAEs563
TESAEs010
SecondaryMaximum Observed Plasma Concentration (Cmax) of A3907

Blood samples were collected at specified timepoints to assess Cmax of A3907. The pharmacokinetic (PK) analysis was conducted after single dose (Day 0) and repeated dose administration (Day 98).

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of A3907
nanogram/milliliter (ng/mL)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Day 047.1 ± 67.9142 ± 53.778.3 ± 240.2
Day 9835.9 ± 71.9134 ± 22.4NA ± NA
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time t (Time of Last Quantifiable Plasma Concentration) (AUC0-t) of A3907

Blood samples were collected at specified timepoints to assess AUC0-t of A3907.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (Time of Last Quantifiable Plasma Concentration) (AUC0-t) of A3907
hour*ng/mLA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Day 0309 ± 76.4866 ± 58.0604 ± 189.4
Day 98223 ± 61.1936 ± 9.3NA ± NA
SecondaryChange From Baseline to Week 12 in Serum and Urine Individual and Total Bile Acid Levels

Blood and urine samples were collected at specified timepoints to assess serum and urine individual and total bile acid levels. Baseline=average of all screening results and results on day of planned single dose if both results were available. Otherwise, baseline=last non-missing assessment prior to study drug administration of planned single dose. CA=Cholic Acid; LCA=lithocholic acid; DCA=deoxycholic acid; CDCA=chenodeoxycholic acid; UDCA= ursodeoxycholic acid; GCA=glycocholic acid; GLCA=glycolithocholic acid; GDCA=glycodeoxycholic acid; GCDCA=glycochenodeoxycholic acid; GUDCA= glycoursodeoxycholic acid; TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid; TDCA=taurodeoxycholic acid; TLCA=taurolithocholic acid; TUDCA=tauroursodeoxycholic acid; S=sulfate. Calculated total bile acids without all UDCA bile acids is the sum of all individual bile acids excluding all UDCAs (UDCA, GUDCA, TUDCA). Conjugated bile acids include GCA, GLCA, GDCA, GCDCA, GUDCA, TCA, TCDCA, TDCA, TLCA, TUDCA.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · micromole/liter (umol/L)
Change From Baseline to Week 12 in Serum and Urine Individual and Total Bile Acid Levels
micromole/liter (umol/L)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Serum CA0.4885 ± 0.9331-0.1753 ± 0.55020.0560 ± 0.0550
Serum LCA0.0151 ± 0.04840.0261 ± 0.0655-0.0104 ± 0.0146
Serum DCA0.2717 ± 0.46950.2679 ± 0.3591-0.0456 ± 0.0528
Serum CDCA0.8167 ± 1.19890.0039 ± 0.12330.1613 ± 0.2870
Serum UDCA4.6122 ± 6.0338-3.5851 ± 5.7702-1.1110 ± 1.4305
Serum GCA1.3351 ± 2.3384-1.8013 ± 5.23960.3603 ± 0.0326
Serum GLCA0.0175 ± 0.19670.0325 ± 0.3491-0.0212 ± 0.0300
Serum GDCA2.1247 ± 2.80125.5493 ± 13.3255-0.3383 ± 0.8731
Serum GCDCA5.0845 ± 7.66962.4643 ± 13.69734.2567 ± 6.7475
Serum GUDCA11.5201 ± 14.02724.2602 ± 28.0844-4.6380 ± 1.2898
Serum TCA0.2912 ± 0.7627-3.0008 ± 4.1924-0.7998 ± 1.5993
Serum TCDCA0.4840 ± 0.9149-1.3761 ± 3.60520.1130 ± 0.3271
Serum TDCA0.1295 ± 0.2088-0.1607 ± 1.4477-0.1464 ± 0.3922
Serum TLCA-0.0002 ± 0.0385-0.0508 ± 0.1124-0.0054 ± 0.0077
Serum TUDCA0.9627 ± 1.5129-1.8607 ± 4.4925-1.2759 ± 0.1619
Serum total bile acids-KI28.1533 ± 36.36830.5934 ± 65.2963-3.4447 ± 6.4230
Serum total bile acids-GCL32.7500 ± 48.07788.3750 ± 86.80280.6667 ± 4.2426
Serum total bile acids (calculated) without all UDCAs bile acid11.0582 ± 16.83461.7790 ± 38.02683.5803 ± 3.8647
Conjugated serum bile acids21.9490 ± 29.86834.0558 ± 69.7236-2.4951 ± 4.6887
Unconjugated serum bile acids6.2043 ± 8.1301-3.4624 ± 6.1819-0.9497 ± 1.7343
Urine CA0.4831 ± 0.38810.0657 ± 0.08420.1562
Urine LCA0.0088 ± 0.01400.0049 ± 0.01040.0000
Urine DCA0.0248 ± 0.02980.0254 ± 0.03480.0000
Urine CDCA0.0103 ± 0.00870.0020 ± 0.00870.0000
Urine UDCA0.1338 ± 0.15130.0935 ± 0.22950.0183
Urine GCA0.4344 ± 0.6883-0.6828 ± 1.83810.2483
Urine GLCA0.0058 ± 0.0091-0.0001 ± 0.00020.0000
Urine GDCA0.1260 ± 0.13970.0191 ± 0.4760-0.0102
Urine GCDCA0.0606 ± 0.0939-0.0682 ± 0.20170.0162
Urine GUDCA17.6985 ± 24.4586-2.6098 ± 22.97010.6844
Urine CA-S-0.0656 ± 0.1611-0.0072 ± 0.00760.0041
Urine LCA-S0.0933 ± 0.09030.2142 ± 0.42390.0000
Urine DCA-S0.0954 ± 0.26970.0327 ± 0.0915-0.0315
Urine CDCA-S-0.0176 ± 0.10470.1086 ± 0.2254-0.0116
Urine UDCA-S-0.7360 ± 5.53271.1988 ± 3.42280.0616
Urine GCA-S-0.1996 ± 0.9580-2.1408 ± 3.5941-0.0137
Urine GLCA-S-2.2804 ± 21.4492-11.3853 ± 13.7351-0.0568
Urine GDCA-S6.3690 ± 16.0747-10.6307 ± 25.1248-1.0202
Urine GCDCA-S1.4066 ± 4.4791-3.9908 ± 7.1694-0.0223
Urine GUDCA-S-1.6910 ± 126.564614.1540 ± 37.1691-2.1189
Urine total bile acids21.9601 ± 179.9461-15.5970 ± 71.0133-2.0963
Urine total bile acids (calculated) without all UDCAs bile acid6.5548 ± 39.9565-28.4334 ± 51.0251-0.7417
Conjugated urine bile acids18.3253 ± 25.3490-3.3419 ± 25.42370.9387
Unconjugated urine bile acids0.6608 ± 0.50740.1914 ± 0.36030.1745
Conjugated urine sulfated bile acids3.6045 ± 157.4674-13.9937 ± 47.9874-3.2320
Unconjugated urine sulfated bile acids-0.6305 ± 5.84071.5471 ± 3.84820.0225
SecondaryChange From Baseline to Week 12 in Liver Biochemical Tests (LBTs): Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Alkaline Phosphatase (ALP)

Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · Units/liter
Change From Baseline to Week 12 in Liver Biochemical Tests (LBTs): Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Alkaline Phosphatase (ALP)
Units/literA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
ALT1.500 ± 37.3698-14.500 ± 47.08150.333 ± 41.0122
AST0.833 ± 33.4644-13.000 ± 25.8618-7.167 ± 22.3917
GGT50.500 ± 49.8849-39.500 ± 132.629268.500 ± 37.9481
ALP55.417 ± 78.7359-16.375 ± 53.354722.667 ± 61.2826
SecondaryChange From Baseline to Week 12 in Liver Biochemical Tests: Total and Direct Bilirubin Levels

Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · umol/L
Change From Baseline to Week 12 in Liver Biochemical Tests: Total and Direct Bilirubin Levels
umol/LA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Total bilirubin-0.700 ± 2.6414-3.988 ± 4.1003-2.117 ± 0.3064
Direct bilirubin0.425 ± 1.7745-1.600 ± 2.8534-0.283 ± 0.1179
SecondaryChange From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)

Blood samples were collected at specified timepoints to assess C4. Baseline was defined as the assessment performed on the day of the planned single dose.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · microgram/liter
Change From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)
microgram/literA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Change From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)-2.333 ± 11.8162-3.860 ± 18.260017.233 ± 27.8011
SecondaryChange From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19)

Blood samples were collected at specified timepoints to assess FGF-19. Baseline was defined as the assessment performed on the day of the planned single dose.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · ng/L
Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19)
ng/LA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19)-23.7 ± 31.56-129.3 ± 190.72-6.5 ± 21.92

Adverse events

Collected over Adverse events were collected from first dose of study drug (Day 1) up to 14 days post last dose, approximately 112 days. Deaths (all-cause mortality) were collected from first dose of study drug (Day 1) up to end of follow-up per participant, maximum of 30 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A3907 10 mg QD0/8 (0%)0/8 (0%)5/8 (62.5%)
A3907 30 mg QD0/6 (0%)1/6 (16.7%)6/6 (100%)
A3907 30 mg BID With CRS0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
CholangitisHepatobiliary disorders0/81/60/4
Most frequent other events
Showing 10 of 27
Most frequent other events
EventA3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRS
DiarrhoeaGastrointestinal disorders0/83/62/4
Crystal urine presentInvestigations0/80/62/4
Abdominal painGastrointestinal disorders1/82/61/4
FlatulenceGastrointestinal disorders0/81/61/4
Alanine aminotransferase increasedInvestigations1/81/61/4
Aspartate aminotransferase increasedInvestigations1/81/61/4
Blood urine presentInvestigations0/80/61/4
White blood cells urine positiveInvestigations0/80/61/4
AstheniaGeneral disorders2/81/60/4
PyrexiaGeneral disorders0/81/61/4

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of A3907.

Age, Continuous
Age, Continuous(years)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRSTotal
Mean42.3 ± 9.8243.0 ± 11.0837.8 ± 14.5741.5 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRSTotal
Female0101
Male85417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRSTotal
Hispanic or Latino1102
Not Hispanic or Latino75416
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A3907 10 mg QDA3907 30 mg QDA3907 30 mg BID With CRSTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White86418
More than one race0000
Unknown or Not Reported0000
08

Study locations

8 sites
  • Hopital Saint Antoine
    Paris, 75012, France
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, Italy
  • ASST di Monza - Azienda Ospedaliera San Gerardo
    Monza, 20900, Italy
  • Azienda Ospedale Università Padova
    Padova, 35128, Italy
  • Centrum Medyczne INTER-MED
    Częstochowa, Poland
  • Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibinskiego
    Katowice, Poland
  • ID Clinic Arkadiusz Pisula
    Mysłowice, Poland
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Access Criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jul 2025, 30 months.

Results were first posted in May 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 8, 2022
StartActual
Jan 9, 2023
Primary completionActual
Jul 10, 2025
CompletionActual
Jul 10, 2025
Results first posted
May 4, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05642468
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Jan 9, 2023
Primary completion
Jul 10, 2025
Completion
Jul 10, 2025
Results posted
May 4, 2026
Last update
May 4, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion